Reflux When to See a Doctor: Causes, Diagnosis, and Treatment

Reflux (acid backing up from the stomach into the esophagus) is an everyday experience for a large share of adults, and most of it is not dangerous. GERD is the diagnosis clinicians use once reflux is frequent, troublesome, or causing tissue damage, generally accepted as occurring more than twice a week for four or more weeks. This article focuses on the decision that most readers actually face: whether today's reflux is a home-care problem or a reason to call a doctor.

What causes reflux?

The lower esophageal sphincter (LES) is a ring of muscle that normally stays closed between swallows. Reflux happens when it relaxes at the wrong time or loses tone, letting stomach contents move upward into a part of the digestive tract that is not built to tolerate acid the way the stomach lining is.

Transient LES relaxations account for most reflux episodes in people without a hiatal hernia. In more severe, chronic esophagitis, a persistently low resting LES pressure becomes a bigger contributor. Both mechanisms respond somewhat differently to treatment, which is one reason a clinician may recommend different medications for someone with occasional reflux versus someone with erosive esophagitis on endoscopy.

Hiatal hernia, where part of the stomach slides above the diaphragm, becomes more common with age and is associated with lower LES pressure, more acid exposure time, and slower clearance once reflux occurs.

Diet and lifestyle factors that reduce LES tone or raise stomach pressure include high-fat meals (which also delay gastric emptying), caffeine, alcohol, chocolate, peppermint, and smoking (which reduces the saliva that normally buffers acid in the esophagus). Obesity, particularly abdominal obesity, is widely regarded as the single strongest modifiable risk factor for new-onset GERD, through increased intra-abdominal pressure.

Medications that can worsen reflux or irritate the esophagus include calcium channel blockers, nitrates, benzodiazepines, tricyclic antidepressants, and NSAIDs. Oral bisphosphonates (such as alendronate) can cause pill-induced esophagitis if taken without enough water or while lying down. Anyone on these medications who develops new or worsening reflux should mention it to the prescriber rather than simply adding an OTC acid reducer.

Typical versus atypical symptoms

Classic GERD looks like heartburn (burning behind the breastbone) and regurgitation (acid or food coming back up without effort or vomiting). Many people recognize this pattern quickly.

Atypical and extraesophageal presentations are less obvious and often delay diagnosis: chronic cough lasting more than eight weeks, hoarseness or laryngitis, dental erosion, and chest pain that mimics cardiac disease (which should always be evaluated for a cardiac cause first). Nighttime reflux is disproportionately linked to respiratory symptoms because lying flat removes the help of gravity and swallowing slows during sleep, reducing the acid-clearing effect of saliva.

A meaningful minority of people with objectively abnormal acid exposure on testing report no heartburn at all, sometimes called silent reflux or laryngopharyngeal reflux (LPR). One symptom that overlaps confusingly with LPR is globus sensation, the feeling of a lump in the throat unrelated to swallowing difficulty. Globus is common, usually benign, and only sometimes reflux-related; distinguishing it from dysphagia (true difficulty swallowing) matters because dysphagia is an alarm symptom and globus generally is not (clinical review on the evaluation of globus sensation). If you have a persistent throat-lump sensation, the useful clinical question is whether swallowing itself is actually impaired, not just whether the sensation is uncomfortable.

When should you actually worry?

Occasional heartburn after a large or spicy meal is not, by itself, a reason for urgent evaluation. The following features change that calculus.

Alarm features that warrant prompt evaluation, not a wait-and-see trial

Anyone with a single item from this list should not wait through a two-week trial of over-the-counter therapy before seeking care; these are reasons to see a clinician promptly, and features like vomiting blood or black stools warrant urgent or same-day evaluation.

Frequency without alarm features

Symptoms occurring more than twice a week for four or more weeks are generally accepted as meeting the threshold for a GERD evaluation, independent of alarm symptoms. This threshold, sometimes called the Montreal criteria in gastroenterology literature, is a reasonable trigger for a clinical visit even when nothing about the symptoms feels dangerous.

Age and cumulative risk

Older adults presenting with new reflux, and people with long-standing GERD (roughly five or more years) combined with obesity and a smoking history, carry a higher likelihood of Barrett's esophagus. This combination is generally why guidelines support a one-time screening endoscopy in higher-risk groups rather than in everyone with heartburn.

A reflux triage decision rule

This is a simplified decision aid, not a diagnostic tool, and does not replace clinical judgment. Use it to decide what to do next, not to diagnose yourself.

The tradeoff built into this table: self-treating mild, infrequent reflux is reasonable and low-risk, but self-treating around an alarm feature just delays a diagnosis that, in a minority of cases, is time-sensitive (stricture, bleeding, or cancer). The cost of an unnecessary doctor visit is inconvenience; the cost of missing an alarm feature can be a delayed cancer or bleeding diagnosis. That asymmetry is why alarm features override frequency-based self-care rules.

How is reflux diagnosed?

No single test is both perfectly sensitive and specific for GERD, so the approach depends on the clinical picture.

Clinical diagnosis with a PPI trial. When someone has classic heartburn and regurgitation without alarm features, a clinician may make a working diagnosis and start an empirical trial of a proton pump inhibitor, typically over about eight weeks, using symptom improvement as evidence for the diagnosis. This is a widely used, guideline-supported approach, though it is not perfectly accurate on its own.

Upper endoscopy (EGD). Endoscopy is used when alarm features are present, when symptoms do not respond to PPI therapy, or when Barrett's esophagus screening is indicated. It can identify erosive esophagitis, strictures, hiatal hernia, Barrett's changes, or cancer, but a normal-looking esophagus does not rule out GERD, because a large share of people with GERD have non-erosive disease with no visible damage.

Ambulatory pH or impedance-pH monitoring. For people with persistent symptoms despite PPI therapy, or atypical presentations, extended monitoring (with a small catheter or wireless capsule) gives objective data on how much and what type of reflux is occurring, including reflux that is not fully acidic.

Esophageal manometry. This test measures LES pressure and esophageal muscle function. It does not diagnose GERD by itself but is typically required before anti-reflux surgery to rule out a motility disorder such as achalasia, which can look like GERD but is treated very differently and can be harmed by fundoplication performed in error.

How is reflux treated?

Treatment generally follows a stepwise approach.

Lifestyle changes, tried first

• Weight management. Modest weight loss is consistently associated with reduced acid exposure and symptom frequency in people with obesity-related GERD; this is generally regarded as the single most effective lifestyle intervention available.
• Head-of-bed elevation. Raising the head of the bed (not just using extra pillows under the head) reduces nighttime acid exposure in people with nocturnal symptoms.
• Meal timing. Avoiding food in the few hours before lying down limits reflux during the period when clearance is least effective.
• Trigger elimination. A time-limited trial of removing high-fat meals, chocolate, peppermint, citrus, tomato-based foods, caffeine, and alcohol can help identify individual triggers, which vary from person to person.

Over-the-counter medication, next

• Antacids (calcium carbonate, magnesium hydroxide) neutralize acid quickly but only for a short time and do nothing to reduce acid production. Best for infrequent, predictable symptoms.
• H2-receptor antagonists (e.g., famotidine) reduce acid secretion, with a longer duration than antacids but reduced effect if used continuously for more than about two weeks.
• OTC-strength PPIs (e.g., omeprazole 20 mg) reduce acid secretion substantially over 24 hours and work best taken 30 to 60 minutes before the first meal of the day. A standard OTC course is limited (commonly about two weeks); recurring symptoms after stopping are a signal to see a clinician rather than repeatedly self-treating.

Prescription therapy

Prescription-strength PPIs are the standard treatment for confirmed erosive esophagitis and heal the esophageal lining in a large majority of patients over about eight weeks, generally more effectively than H2-blockers alone. More severe esophagitis (higher grades) often needs ongoing maintenance therapy, since relapse after stopping is common.

A practical, clinician-guided approach some patients use for stepping down long-term PPI therapy once it is no longer clearly needed:

1. Confirm the original diagnosis (ideally with objective testing) before assuming lifelong therapy is required.
2. Optimize lifestyle measures before reducing medication dose.
3. Taper from twice-daily to once-daily dosing over a period of weeks.
4. Trial every-other-day dosing, then switch to an as-needed H2-blocker if symptoms stay controlled.
5. Resume full-dose therapy and seek evaluation immediately if any alarm symptom appears during a taper.

Add-on and specialist options

Baclofen, a GABA-B agonist, is used off-label to reduce transient LES relaxations in patients with persistent regurgitation despite PPI therapy. It is a prescription-only, specialist-guided option, not a first-line treatment.

Sucralfate forms a protective coating over irritated or ulcerated tissue and is sometimes used for pill-induced esophagitis or during pregnancy, where PPI use should be discussed with a clinician.

Alginate-based products (such as Gaviscon Advance) form a physical barrier ("raft") over stomach contents and are a reasonable step between antacids and acid-suppressing medication for some patients.

Procedural and surgical options

Laparoscopic Nissen fundoplication remains the standard surgical option for appropriately selected patients: those who respond to PPIs but prefer not to take lifelong medication, those with large hiatal hernias, or those with volume regurgitation not controlled by acid suppression. Surgery carries its own risks, including dysphagia and gas-bloat symptoms, and manometry to exclude achalasia is a standard prerequisite.

Less invasive endoscopic options, such as transoral incisionless fundoplication, and device-based options, such as magnetic sphincter augmentation (LINX), exist for selected patients with smaller hernias; long-term data beyond about five years remain more limited than for standard surgery.

One area where guidance is genuinely unsettled: peroral endoscopic myotomy (POEM), a procedure primarily used for achalasia, has a recognized tendency to cause or worsen GERD afterward, and a recent survey of specialist practice found meaningful disagreement among experts on how to manage post-POEM reflux (expert panel survey on GERD management after esophageal POEM). If you have had POEM and develop new or worsening reflux afterward, this is a scenario where practice varies by center and a second opinion is reasonable rather than a sign that something has gone wrong.

Barrett's esophagus and cancer risk

Barrett's esophagus is a change in the esophageal lining, from normal squamous tissue to intestinal-type tissue, driven by chronic acid exposure. It is found in a meaningful minority of patients who undergo endoscopy for chronic GERD.

Who is generally considered for screening: guidelines commonly focus on men with long-standing GERD (roughly five or more years) plus additional risk factors such as older age, central obesity, current or past smoking, or a first-degree relative with Barrett's esophagus or esophageal adenocarcinoma. Women have a meaningfully lower risk of Barrett's than men with comparable reflux severity, which is part of why screening recommendations differ by sex.

Progression risk: the annual risk of progression from non-dysplastic Barrett's esophagus to cancer is low on a per-year basis, rises somewhat with low-grade dysplasia, and becomes substantially higher with confirmed high-grade dysplasia. Exact per-year percentages vary across studies and cohorts; if this number will affect a real decision (for example, deciding on surveillance intervals or eradication therapy), that decision should rest on your endoscopist's assessment and current guideline figures rather than any single number quoted online.

Endoscopic eradication therapy (radiofrequency ablation, endoscopic mucosal resection) has largely replaced esophagectomy for high-grade dysplasia in otherwise healthy patients.

Special situations

Pregnancy. Reflux is very common in pregnancy, especially in the third trimester, from increased abdominal pressure and progesterone-related LES relaxation. Calcium carbonate antacids and sucralfate are generally considered first-line because they are not meaningfully absorbed systemically. Famotidine is an option when antacids are insufficient. PPI use in pregnancy should be a discussion with the prescribing clinician, factoring in symptom severity and current safety data, rather than a decision made from an OTC label alone.

Older adults. Atypical presentations, larger hiatal hernias, and impaired esophageal motility are more common with age, and polypharmacy interactions matter. Long-term PPI use in older adults has been linked in observational studies to a modestly increased risk of Clostridioides difficile infection, low magnesium, and possibly fracture risk, though causality for the fracture association remains debated. Periodic reassessment of whether ongoing PPI therapy is still needed is reasonable for anyone on it for more than a year.

Infants and children. Spitting up is near-universal in infants under a year old and usually resolves on its own. Reflux that causes poor weight gain, feeding aversion, recurrent aspiration, or apparent life-threatening events is a different, more serious category requiring pediatric evaluation. Medication decisions for infants and children should be made with a pediatrician, not through self-directed OTC treatment.

What to expect at a doctor's visit

Bring a symptom diary covering at least two weeks noting frequency, timing relative to meals, and suspected triggers. List every medication and supplement you take, including OTC antacids and NSAIDs. Mention any prior endoscopy and its findings, and any family history of esophageal or gastric cancer.

Expect your clinician to ask specifically about alarm symptoms. If none are present and your symptoms are classic, an empirical PPI trial is a common first step. Full resolution on that trial supports a GERD diagnosis and a discussion of long-term management. Incomplete relief, or rapid relapse every time you stop the medication, is a reason for further testing rather than an indefinite cycle of restarting OTC treatment on your own.

What is established, what is not

Established: reflux is common and usually benign; alarm symptoms warrant prompt evaluation rather than self-care; PPIs are effective for healing erosive esophagitis; obesity and certain medications and foods worsen reflux; Barrett's esophagus is a recognized precursor lesion for esophageal adenocarcinoma in a subset of chronic GERD patients.

Plausible but not settled from the material available here: exact percentage risks for Barrett's progression, precise fracture-risk figures with long-term PPI use, and the best standardized management pathway for reflux that develops after procedures like POEM, where specialist opinion is documented to vary. Readers should treat precise numbers on these points as approximate until confirmed with a clinician or the current primary literature, and this article does not carry forward several specific statistics from older drafts because their original source citations could not be verified.